XtalPi Stock

Pharmaceutical technology company XtalPi has announced a collaboration with US drug maker Eli Lilly. The partnership will focus on using AI and robotics in drug discovery, with an upfront payment of up to $250 million. XtalPi will use its ID4Inno™ small-molecule drug discovery platform, combining AI, autonomous labs, and expert domain knowledge for efficient drug discovery processes.

XtalPi has entered into a $250m partnership with Eli Lilly to utilise artificial intelligence (AI) for drug discovery. The collaboration will leverage XtalPi’s integrated AI capabilities and robotics platform to design and deliver drug candidates. The AI drug discovery solution will be used to create a novel compound, which will be advanced by Lilly through clinical and commercial development.

XtalPi, a pharmaceutical firm backed by Tencent and Softbank, plans to leverage AI to expand into materials science and discover new industrial materials. The company also intends to significantly expand its facilities in Shanghai and Hong Kong, but has no immediate plans for an IPO.